Joan Merrill
Rheumatology · Oklahoma City, OKNPI 1962471813
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $840,854 of the $864,398 with a category attached, or 97.3%. It is spread thinly across 24 manufacturers, the largest accounting for just 23.6%. Among rheumatology clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 230 payments — averaging $3758.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$204K
- Merck$125K
- E.r. Squibb & Sons, L.L.C.$87K
- Sanofi US Services Inc.$86K
- Bristol Myers Squibb$68K
- AbbVie$67K
- plus $228K from 18 others
Across 137 payments — averaging $10,674 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$612K
- AbbVie$286K
- Amgen$257K
- GSK$150K
- EMD Serono Research & Development Institute, Inc.$111K
- E.r. Squibb & Sons, L.L.C.$24K
- plus $22K from 5 others
What the payments were for
- Consulting fees$840,85497%
- Speaking & faculty fees$4,9751%
- Travel & lodging$16,5422%
- Food & beverage$1,9720%
- Education$550%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 19 | $204,334 |
| Merck | 50 | $124,826 |
| E.r. Squibb & Sons, L.L.C. | 38 | $86,799 |
| Sanofi US Services Inc. | 11 | $85,923 |
| Bristol Myers Squibb | 12 | $68,424 |
| AbbVie | 32 | $66,585 |
| EMD Serono, Inc. | 9 | $60,193 |
| EMD Serono Research & Development Institute, Inc. | 2 | $54,450 |
| UCB SA | 12 | $48,921 |
| Sanofi-aventis U.S. LLC | 3 | $14,488 |
| GSK | 8 | $9,608 |
| Eli Lilly | 6 | $6,421 |
| Astrazeneca UK Limited | 3 | $6,111 |
| Biogen | 3 | $5,750 |
| F. Hoffmann-la Roche AG | 4 | $5,479 |
| AstraZeneca(2 entities) | 5 | $5,026 |
| Janssen Research & Development, LLC | 6 | $4,364 |
| UCB GmbH | 1 | $2,880 |
| Aurinia Pharma U.S., Inc. | 1 | $2,000 |
| Genentech, Inc. | 1 | $1,150 |
| Astrazeneca AB | 1 | $537 |
| Johnson & Johnson | 1 | $55 |
| Janssen Scientific Affairs, LLC | 1 | $46 |
| Daiichi Sankyo Inc. | 1 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$864,398 in reported general payments places this provider in the 95th percentile of 67 rheumatology providers in Oklahoma.
Other rheumatology in Oklahoma City
- Latisha HeinlenOklahoma City$675K
- Mohammad KhanOklahoma City$94K
- Cristina ArriensOklahoma City$82K
- John GoetzingerOklahoma City$18K
- Robert ArthurOklahoma City$16K
- Muhammad GillanOklahoma City$16K
- William SchnitzOklahoma City$15K
- Judith JamesOklahoma City$15K
- Amanda TitusOklahoma City$13K
- Michael PickrellOklahoma City$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.